The Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease
. The review comes ahead of a meeting this week for outside experts to vote on the drug for ALS. The drug has been the focal point of a lobbying campaign by patients, their families and lawmakers. FDA reviewers said Monday, March 28, 2022 the single study from Amylyx Pharmaceuticals was “not persuasive” due to missing data, errors in enrolling patients and other problems.
The FDA's negative stance on the drug sets up a tense scenario at Wednesday's public session, where several dozen ALS patients and advocates are scheduled to speak. The agency will consider the input from its advisory panel before making a final decision on the drug, expected by June. But the reviewers found the drug had “only a modest” effect on slowing the disease's progression in a 137-patient, mid-stage study, which reviewers said was plagued with implementation and analysis problems. Typically, FDA approval requires two large studies or one study with a “very persuasive” effect on survival.
But FDA says the results are unreliable because of problems tracking the study participants for several years. The ALS Association, which helped fund Amylyx’s research, said the FDA’s review does not take into account “the speed and severity of ALS and the few treatment options available.”
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA skeptical of benefits from experimental ALS drugThe drug from Amylyx Pharmaceuticals has become a rallying cause for patients with the deadly neurodegenerative disease ALS, their families and members of Congress who’ve joined in pushing the FDA to greenlight the drug.
Weiterlesen »
ABC News: FDA could authorize second booster shots for Americans over 50 this weekTwo officials familiar with the matter tell ABC News the FDA could authorize second booster shots for Americans over 50 years old as soon as Tuesday, but the details are still under discussion.
Weiterlesen »
Milk of Magnesia products being recalled over possible contamination, FDA saysMilk of Magnesia products and other medications are being recalled over possible contamination, according to the Food and Drug Administration.
Weiterlesen »
FDA: Nationwide recall of Milk of Magnesia, other medicines due to possible contaminationPlastikon Healthcare, based in Kansas, is voluntarily recalling a select number of products sold nationally due to possible bacteria contamination.
Weiterlesen »
Nationwide recall of Milk of Magnesia due to possible bacterial contamination: FDAThe popular over-the-counter product for heartburn and constipation could cause intestinal distress instead if it's from the contaminated lots.
Weiterlesen »
Nationwide recall of Milk of Magnesia due to possible bacterial contamination: FDAThe popular over-the-counter product for heartburn and constipation could cause intestinal distress instead if it's from the contaminated lots.
Weiterlesen »